Article Sidebar

PDF
Date Published: 20/04/2023
Abstract Views: 284
Views PDF: 144
DOI: https://doi.org/10.51298/vmj.v525i1B.5144
Issue
Vol. 525 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. H. ., & Nguyễn, V. H. . (2023). EVALUATION ON UNWANTED EFFECTS OF R-GDP REGIME IN TREATMENT OF B CELL NON HODGKIN LYMPHOMA RELAPSED AT BACH MAI HOSPITAL. Vietnam Medical Journal, 525(1B). https://doi.org/10.51298/vmj.v525i1B.5144

EVALUATION ON UNWANTED EFFECTS OF R-GDP REGIME IN TREATMENT OF B CELL NON HODGKIN LYMPHOMA RELAPSED AT BACH MAI HOSPITAL

Tuấn Hùng Nguyễn1, Văn Hưng Nguyễn1,
1 Bach Mai hospital

Main Article Content

Abstract

Objectives: To  evaluate  the  side  effects  of  R- GDP regimen of  treating  B cell non Hodgkin lymphoma relapsed. Objects and Methods: Cross-sectional description on 61 patients with relapsed B-cell non Hodgkin lymphoma treated with R-GDP regimen at Hematology and Blood Transfusion Center, Bach Mai Hospital from January 2013 to July 2021. Results and conclusions: 61 patients treated for 251 cycles with R-GDP regimen. Clinical undesirable effects: nausea - vomiting grade I and II: 41.4% and 25.1%. Rarely symptoms: diarrhea, chills, inflammation of the oral mucosa. On the hematopoietic system: leukopenia, thrombocytopenia grade III - IV were: 63.4% and 40.7% of cycles, grade III - IV hemoglobin reduction was 17.1%. On liver and kidney: the rate of cycles without affecting renal function urea and creatinine was 85.7% and 82.1%, the rate of cycles without increasing AST and ALT was 82.1 and 80.5%.

Article Details

Keywords

non Hodgkin lymphoma, R- GDP regimen

References

1. Vũ Minh Phương (2019). U lympho không Hodgkin. Bài giảng sau đại học Huyết học Truyền máu, Nhà xuất bản Y học, Hà Nội, 323-335.
2. Hoffbrand A. V., Steensma D. P. (2019). Non - Hodgkin lymphoma. Hoffbrand's essential haematology, John Wiley & Sons, 214-225.
3. Moccia A. A., Hitz F., Hoskins P. et al (2017). Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & lymphoma, 58 (2), 324-332..
4. Đỗ Anh Tú (2012). Nghiên cứu đặc điểm lâm sàng và điều trị u lympho ác tính không Hodgkin thể lan tỏa tế bào B lớn, Luận án tiến sỹ y học, Trường Đại học Y Hà Nội, Hà Nội,
5. Gokmen A., Soydan E., Gokgoz Z. et al (2018). Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma. 36 (15), e19517.
6. Fan Y., Huang Z.-Y., Luo L.-H. et al (2008). Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin’s lymphoma: a report of 24 cases. Ai zheng, 27 (11), 1222-1225.
7. Nguyễn Lan Phương (2019). Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị của bệnh nhân u lympho tế bào B lớn lan tỏa tái phát tại viện Huyết học - Truyền máu Trung ương, Luận văn bác sĩ chuyên khoa cấp II, Trường Đại học Y Hà Nội, Hà Nội,
8. Zhong D. T., Shi C. M., Chen Q. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma. Annals of hematology, 91 (11), 1757-1763
9. Crump M., Baetz T., Couban S. (2004). Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B cell non Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCICCTG). Cancer: Interdisciplinary International Journal of the American Cancer Society, 101 (8), 1835-1842.
10. Villa D., Seshadri T., Puig N. (2012). Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin’s lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica, 97 (5), 751-757.